pulmonary arterial hypertension

Evaluating Riociguat in Early Pulmonary Vascular Disease: Insights from the ESRA Phase IIa Trial

By MedXY 07/17/2026

The ESRA trial demonstrates that riociguat is safe and effectively reduces pulmonary vascular resistance in early pulmonary vascular disease, though secondary benefits remain unproven in this early-stage, mostly connective tissue disease-associated cohort.

Cardiology news Respiratory

Decoding Pulmonary Arterial Hypertension in Congenital Heart Disease: Latent Class Analysis Uncovers Distinct Risk Phenotypes and Treatment Insights

By MedXY 06/25/2026

Latent class analysis of 889 adult PAH-CHD patients identified unique phenogroups with distinct survival outcomes and treatment responses, offering refined risk stratification and guiding personalized therapy.

Cardiology news Respiratory

From Compensation to Collapse: How Cardiac Myofibroblasts and UCP2 Genetic Variants Dictate Right Ventricular Fate in PAH

By MedXY 03/09/2026

This study identifies the transition of cardiac fibroblasts to myofibroblasts as a critical driver of right ventricular failure in PAH, highlighting the role of UCP2 deficiency and the rs659366 SNP as key clinical indicators of decompensation.

Cardiology Gastroenterology news

Early Portopulmonary Hypertension in Cirrhosis: A Prognostic Marker of Increased Mortality

By MedXY 10/27/2025

Early-stage portopulmonary hypertension, defined by revised 2022 ESC/ERS criteria, independently predicts mortality in patients with cirrhosis, underscoring the importance of systematic screening and early intervention.

Cardiology news Respiratory

Early Intervention in Pulmonary Arterial Hypertension: The Promise of Sotatercept in the First Year Post-Diagnosis

By MedXY 10/25/2025

This article reviews a phase 3 trial analyzing sotatercept's efficacy and safety in newly diagnosed pulmonary arterial hypertension patients, highlighting its potential to reduce clinical worsening early in the disease course.

Clinical Updates news Respiratory Specialties

Sotatercept in High-Risk Pulmonary Arterial Hypertension: A Landmark Advance in Patient Outcomes

By MedXY 08/02/2025

Sotatercept significantly reduces the risk of death, lung transplantation, or hospitalization in high-risk pulmonary arterial hypertension patients, marking a major advance in the management of this life-threatening disease.